Home - Belmore Neidrauer LLP

Persuasive Advocacy.
Proven Results.

We are experts in intellectual property litigation. We are trial lawyers.
We are appellate lawyers. We know patent law, inside and out.
Learn More

News

Belmore Neidrauer LLP Recognized by Legal 500 2024

Belmore Neidrauer LLP was named an “Elite Boutique” in the Legal 500 2024 Rankings, with partner Peter Wilcox highlighted as a Leading Individual. Marian Wolanski and Stephanie Anderson have also been recognized as Next Generation Partners
Peter Wilcox recognized at the LMG Life Sciences Americas Awards

Belmore Neidrauer partner Peter Wilcox was recognized as Patent Litigator of the Year - Canada at the 2023 LMG Life Sciences Americas Awards. North America Award Winners (lmglifesciences.com)
LMG Life Sciences recognizes Belmore Neidrauer

Belmore Neidrauer was recognized for acting on behalf of Janssen in the LMG Life Sciences Patent Impact Case of the Year Teva v Janssen (2023 FCA 68) at the 2023 LMG Life Sciences Americas Awards.
Peter Wilcox recognized in the Who’s Who Legal: IP 2023 Guide

Belmore Neidrauer partner Peter Wilcox has been recognized in the Who’s Who Legal: IP 2023 Guide as a Global Elite Thought Leader. The guide, based on feedback from clients and peers, describes Peter as a “very strong and tough litigator.” The guide is available here: Whoswholegal - Market Insight
Belmore Neidrauer Shortlisted for LMG Life Sciences Awards Americas 2023

Belmore Neidrauer is pleased to announce that the firm has been shortlisted for Patent Litigation Firm of the Year - Canada at the upcoming LMG Life Sciences Awards Americas 2023. Belmore Neidrauer partner Peter Wilcox has also been shortlisted for Patent Litigator of the Year – Canada.LMG North America Awards Shortlists
IAM Patent 1000 recognizes Belmore Neidrauer LLP

IAM Patent 1000 has once again ranked Belmore Neidrauer LLP as a leading patent litigation firm with a "dedicated team of IP lawyers who boast a client-oriented approach and practical solutions.” Partners Peter Wilcox, Marian Wolanski and Stephanie Anderson are also recognized as leading patent litigators.

Our Team

Mary is a law clerk specializing in intellectual property litigation matters.
Mary Mutchler

Law Clerk

p.(416) 863-3357

f.(416) 863-9171

e.mmutchler@belmorelaw.com

See The Full Team

Our cases

March 23, 2023

Janssen Inc. et al v. Teva Canada Limited

Counsel: Peter Wilcox, Marian Wolanski and Megan Pocalyuko

We successfully represented Janssen on Teva’s appeal and Janssen’s cross-appeal in a significant decision relating to the law of inducing patent infringement in Canada. The decision relates to Janssen’s patent covering INVEGA SUSTENNA® (paliperidone ...
Read more
October 27, 2022

Janssen v. Apotex

Counsel: Peter Wilcox and Stephanie Anderson

We successfully represented Janssen in a motion to appeal an order of the Associate Judge which declined, based on relevance, to compel Apotex to answer certain discovery questions related to its ability to supply its generic abiraterone acetate prod...
Read more
October 27, 2022

Janssen v. Apotex

Counsel: Peter Wilcox and Stephanie Anderson

We successfully represented Janssen in a motion to Amend its Statement of Defence in this PMNOC section 8 damages action. The Court agreed that Janssen was allowed to amend its Statement of Defence to raise issues as to Apotex’s ability to supply the...
Read more
December 05, 2022

Janssen v. Dr. Reddy

Counsel: Peter Wilcox and Stephanie Anderson

We successfully represented Janssen in this motion brought by Dr. Reddy’s in the context of a PMNOC section 8 damages action. Dr. Reddy’s was seeking to have a question of law determined before trial. The question of law related to whether Janssen co...
Read more
January 19, 2023

Janssen v. Pharmascience

Counsel: Peter Wilcox and Marian Wolanski

We successfully represented Janssen in a motion brought by the appellant (Pharmascience) to settle the contents of the appeal book in the context of an appeal from the judgment of the Federal Court in Janssen Inc. v. Pharmascience Inc., 2022 FC 1218 ...
Read more
January 24, 2023

Alexion v. Attorney General of Canada

Counsel: Peter Wilcox, Marian Wolanski and Kelly Zhang

This was an application to add an inventor to two patents owned by Alexion Pharmaceuticals. The patents relate to Alexion’s blockbuster drug SOLIRIS. The application was granted, ensuring that the correct inventors are named on the patents relating t...
Read more
February 14, 2023

Apotex Inc. v Janssen Inc. et al

Counsel: Peter Wilcox, Stephanie Anderson, Heather Lindsay and Kelly Zhang

We successfully represented Janssen on these motions seeking non-party discovery in three PMNOC section 8 actions.Each of Apotex, Dr. Reddy’s and Pharmascience resisted, on numerous grounds, non-party discovery for use in these section 8 actions. The...
Read more
August 23, 2022

Janssen v. Pharmascience

Counsel: Peter Wilcox, Marian Wolanski, Megan Pocalyuko and Oleyna Strigul

We successfully represented Janssen in defending the validity of the patent relating to Janssen’s INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product used to treat schizophrenia.
Read more
January 31, 2022

Janssen v Apotex

Counsel: Peter Wilcox, Marian Wolanski and Megan Pocalyuko

We successfully represented Janssen in this summary trial in the Federal Court on infringement issues against Apotex in respect of Janssen’s patent covering its important INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product used t...
Read more
January 19, 2022

Janssen v Pharmascience

Counsel: Peter Wilcox, Marian Wolanski and Megan Pocalyuko

We successfully represented Janssen in this summary trial in the Federal Court on infringement issues against Pharmascience in respect of Janssen’s patent covering its important INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product...
Read more
January 14, 2021

Janssen v Apotex, Pharmascience and Dr. Reddy’s Laboratories

Counsel: Peter Wilcox, Marian Wolanski, Stephanie Anderson and Megan Pocalyuko

We represented Janssen and BTG in these patent infringement actions relating to Janssen’s prostate cancer product ZYTIGA®(abiraterone acetate). We were successful in proving inducing infringement and in resisting the defendants’ attacks based on lack...
Read more
July 28, 2021

Seedlings v. Pfizer

Counsel: Peter Wilcox and Stephanie Anderson

We successfully represented Pfizer on this appeal related to a mechanical device patent and Pfizer’s epinephrine auto injector product EpiPen®. The Federal Court of Appeal upheld the trial judge’s decision on claim construction, anticipation, obvious...
Read more
July 13, 2018

Eli Lilly Canada Inc. et al v. Apotex Inc.

Counsel: Marian Wolanski

We represented Eli Lilly, Daiichi and Ube in this application relating to a patent covering Eli Lilly’s EFFIENT product.
Read more
March 04, 2021

Apotex v. Janssen

Counsel: Peter Wilcox and Stephanie Anderson

We successfully represented Janssen on this appeal. The Federal Court of Appeal upheld the trial judge’s decision that the patent was valid and infringed. On validity, the Court clarified the nature of evidence that can be used to establish demonstra...
Read more
January 14, 2021

Elea v Simplot

Counsel: Peter Wilcox

We successfully represented Elea on this appeal. J.R Simplot, the defendant in a patent infringement action brought by McCain, had issued a third party claim against Elea, alleging that Elea was responsible for any damages that Simplot may be require...
Read more
January 02, 2020

Seedlings Life Sciences v Pfizer

Counsel: Peter Wilcox and Marian Wolanski

We successfully represented Pfizer in this patent infringement action. Seedlings – a non-practicing entity – alleged that Pfizer’s EpiPen infringed a Seedlings patent. Seedlings was seeking all of the profits earned by Pfizer on EpiPen sales since 20...
Read more
May 05, 2020

Janssen Inc. et al v Teva Canada Limited

Counsel: Peter Wilcox and Marian Wolanski

We successfully represented Janssen in this patent infringement action under the new PMNOC Regulations concerning Janssen’s Invega Sustenna (paliperidone palmitate) product used to treat schizophrenia.
Read more
October 29, 2019

Janssen Inc. et al v Apotex Inc.

Counsel: Peter Wilcox and Marian Wolanski

We successfully represented Janssen and BTG in this PMNOC application, the last of such proceedings to be heard under the “old” application procedures. Justice Phelan agreed that Apotex’s allegations of non-infringement and invalidity were not justif...
Read more
April 10, 2018

AbbVie Corporation et al v Samsung Bioepis Co. Ltd.

Counsel: Peter Wilcox and Marian Wolanski

We represented AbbVie in a series of eight applications under the PMNOC Regulations relating to AbbVie’s blockbuster drug HUMIRA.
Read more
April 09, 2018

Samsung Bioepis Co., Ltd. v AbbVie Biotechnology Ltd. et al.

Counsel: Peter Wilcox and Marian Wolanski

We represented AbbVie in a series of eight applications under the PMNOC Regulations relating to AbbVie’s blockbuster drug HUMIRA.
Read more

See all cases

Awards

Consistently Recognized
for Excellence.

We are consistently recognized as leading IP litigators in Canada. Among others, we are recognized by:

Legal 500 Canada Elite Boutique 2024
IAM Patent 1000 Recognized for Patent Litigation 2023
Legal 500 Canada Elite Boutique 2023
Globe and Mail Canada’s Best Law Firms 2023 (Intellectual Property) 2023
Chambers Recognized for Intellectual Property: Litigation 2023
LMG Life Science Recommended for Patent Litigation (Branded) 2022
Managing IP IP Stars 2022 – Recognized for Patent Contentious 2022
IAM Patent 1000 Recognized for Patent Litigation 2022

See all awards

Persuasive Advocacy.Proven Results.

News

Our Team

Our cases

Awards

Consistently Recognizedfor Excellence.

Persuasive Advocacy.
Proven Results.

Consistently Recognized
for Excellence.